Clinical Trial

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Study acronym: PRISM-1
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.
Protocol Amendment History 1 change
notable Trial sites reduced: 125 -> 111 locations 2026-05-09
Trial Details
NCT Number NCT06608927
Lead Sponsor Arcus Biosciences, Inc.
Collaborators: Taiho Pharmaceutical Co., Ltd.
Conditions Metastatic Pancreatic Ductal Adenocarcinoma
Enrollment 610 participants
Start Date 2024-12-13
Primary Completion 2030-11-30 (estimated)
Study Completion 2030-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-31